Company Description
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases.
It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components.
It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States.
Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
| Country | United States |
| Founded | 2011 |
| IPO Date | Jul 15, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 214 |
| CEO | Paul Badawi |
Contact Details
Address: 4040 Campbell Ave, Suite 100 Menlo Park, California 94025 United States | |
| Phone | (415) 889-0550 |
| Website | sightsciences.com |
Stock Details
| Ticker Symbol | SGHT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $24.00 |
| CIK Code | 0001531177 |
| CUSIP Number | 82657M105 |
| ISIN Number | US82657M1053 |
| Employer ID | 80-0625749 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Paul Badawi | Co-Founder, President, Chief Executive Officer and Director |
| Dr. David Badawi M.D. | Founder, Chief Technology Officer and Director |
| Sam Boong Park | Chief Operating Officer |
| Alison Perry Bauerlein | Chief Financial Officer and Treasurer |
| Jeremy B. Hayden | Chief Legal Officer |
| Steve R. Tamayo Jr. | Vice President and Chief Ethics and Compliance Officer |
| Dr. Reay H. Brown | Chief Medical Officer |
| Tom Huang | Head of Corporate Strategy and Development |
| Matthew W. Link | Chief Commercial Officer |
| Stephen B. Thau J.D. | Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 17, 2024 | 144 | Filing |
| May 6, 2024 | 10-Q | Quarterly Report |
| May 2, 2024 | 8-K | Current Report |
| Apr 29, 2024 | 8-K | Current Report |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2024 | 144 | Filing |
| Apr 3, 2024 | 144 | Filing |
| Apr 3, 2024 | 144 | Filing |
| Apr 3, 2024 | 144 | Filing |